Research graph
References from Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)
10.1016/j.eururo.2021.08.010 · 2022 · External reference
Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis
10.1016/j.juro.2016.12.090 · 2017 · External reference
LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
10.1016/j.annonc.2023.10.110 · 2023 · External reference
BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
10.1038/nrurol.2017.16 · 2017 · External reference
Evidence-based assessment of current and emerging bladder-sparing therapies for non–muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis
10.1016/j.euo.2020.02.006 · 2020 · External reference
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
10.1016/s1470-2045(20)30540-4 · 2021 · External reference
European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines
10.1016/j.eururo.2023.08.016 · 2024 · External reference
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer
10.1016/j.eururo.2011.12.010 · 2012 · External reference
Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer
10.1056/nejmoa2408154 · 2024 · External reference
Survival of patients with muscle-invasive urothelial cancer of the bladder with residual disease at time of cystectomy: A comparative survival analysis of treatment modalities in the national cancer database
10.3233/blc-200303 · 2020 · External reference
Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes
10.1016/j.euo.2018.09.004 · 2019 · External reference
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma
10.1016/s0022-5347(05)64047-5 · 2003 · External reference
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine
10.1158/1078-0432.ccr-05-1045 · 2005 · External reference
A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene
10.1186/1756-0500-2-66 · 2009 · External reference
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome
10.1016/j.eururo.2013.08.052 · 2014 · External reference
Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer
10.1038/s41698-025-01080-8 · 2025 · External reference
Intravesical gemcitabine for non-muscle invasive bladder cancer: an abridged Cochrane Review
10.4111/icu.20210265 · 2021 · External reference
Inlexzo (gemcitabine intravesical system): promising data but key questions remain
10.1007/s00345-025-05955-0 · 2025 · External reference
Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer
10.1016/j.eururo.2015.07.009 · 2015 · External reference
Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma
10.1001/jamaoncol.2016.1056 · 2016 · External reference
Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial
10.1016/j.eururo.2024.06.018 · 2024 · External reference
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
10.1016/j.ccr.2014.01.009 · 2014 · External reference
Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy
10.1016/j.eururo.2017.03.030 · 2017 · External reference
Association of molecular subtypes with pathologic response, PFS, and OS in a Phase II study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer
10.1158/1078-0432.ccr-23-0602 · 2024 · External reference
Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders
10.1158/2159-8290.cd-21-0538 · 2022 · External reference
Implementing a functional precision medicine tumor board for acute myeloid leukemia
10.1158/2159-8290.cd-21-0410 · 2022 · External reference
Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
10.1038/s43018-023-00645-5 · 2023 · External reference
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients
10.1038/s41523-023-00583-6 · 2023 · External reference
Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer
2023 · External reference
Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers
10.1038/s41591-024-02848-4 · 2024 · External reference
Bladder cancer organoids as a functional system to model different disease stages and therapy response
10.1038/s41467-023-37696-2 · 2023 · External reference
An ex vivo tissue culture model for the assessment of individualized drug responses in prostate and bladder cancer
10.3389/fonc.2018.00400 · 2018 · External reference
Tumor evolution and drug response in patient-derived organoid models of bladder cancer
10.1016/j.cell.2018.03.017 · 2018 · External reference
Integrative drug screening and multiomic characterization of patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response
10.1016/j.eururo.2024.05.026 · 2024 · External reference
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial
10.1186/s12894-023-01262-1 · 2023 · External reference
Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma
10.1001/jamaoncol.2016.1056 · ExternalCitation · doi-reference
Inlexzo (gemcitabine intravesical system): promising data but key questions remain
10.1007/s00345-025-05955-0 · ExternalCitation · doi-reference
LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
10.1016/j.annonc.2023.10.110 · ExternalCitation · doi-reference
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
10.1016/j.ccr.2014.01.009 · ExternalCitation · doi-reference
Tumor evolution and drug response in patient-derived organoid models of bladder cancer
10.1016/j.cell.2018.03.017 · ExternalCitation · doi-reference
Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes
10.1016/j.euo.2018.09.004 · ExternalCitation · doi-reference
Evidence-based assessment of current and emerging bladder-sparing therapies for non–muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis
10.1016/j.euo.2020.02.006 · ExternalCitation · doi-reference
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer
10.1016/j.eururo.2011.12.010 · ExternalCitation · doi-reference
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome
10.1016/j.eururo.2013.08.052 · ExternalCitation · doi-reference
Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer
10.1016/j.eururo.2015.07.009 · ExternalCitation · doi-reference
Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy
10.1016/j.eururo.2017.03.030 · ExternalCitation · doi-reference
European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)
10.1016/j.eururo.2021.08.010 · ExternalCitation · doi-reference
European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines
10.1016/j.eururo.2023.08.016 · ExternalCitation · doi-reference
Integrative drug screening and multiomic characterization of patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response
10.1016/j.eururo.2024.05.026 · ExternalCitation · doi-reference
Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial
10.1016/j.eururo.2024.06.018 · ExternalCitation · doi-reference
Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis
10.1016/j.juro.2016.12.090 · ExternalCitation · doi-reference
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma
10.1016/s0022-5347(05)64047-5 · ExternalCitation · doi-reference
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
10.1016/s1470-2045(20)30540-4 · ExternalCitation · doi-reference
BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
10.1038/nrurol.2017.16 · ExternalCitation · doi-reference
Bladder cancer organoids as a functional system to model different disease stages and therapy response
10.1038/s41467-023-37696-2 · ExternalCitation · doi-reference
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients
10.1038/s41523-023-00583-6 · ExternalCitation · doi-reference
Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers
10.1038/s41591-024-02848-4 · ExternalCitation · doi-reference
Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer
10.1038/s41698-025-01080-8 · ExternalCitation · doi-reference
Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
10.1038/s43018-023-00645-5 · ExternalCitation · doi-reference
Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer
10.1056/nejmoa2408154 · ExternalCitation · doi-reference
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine
10.1158/1078-0432.ccr-05-1045 · ExternalCitation · doi-reference
Association of molecular subtypes with pathologic response, PFS, and OS in a Phase II study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer
10.1158/1078-0432.ccr-23-0602 · ExternalCitation · doi-reference
Implementing a functional precision medicine tumor board for acute myeloid leukemia
10.1158/2159-8290.cd-21-0410 · ExternalCitation · doi-reference
Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders
10.1158/2159-8290.cd-21-0538 · ExternalCitation · doi-reference
A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene
10.1186/1756-0500-2-66 · ExternalCitation · doi-reference
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial
10.1186/s12894-023-01262-1 · ExternalCitation · doi-reference
Survival of patients with muscle-invasive urothelial cancer of the bladder with residual disease at time of cystectomy: A comparative survival analysis of treatment modalities in the national cancer database
10.3233/blc-200303 · ExternalCitation · doi-reference
An ex vivo tissue culture model for the assessment of individualized drug responses in prostate and bladder cancer
10.3389/fonc.2018.00400 · ExternalCitation · doi-reference
Intravesical gemcitabine for non-muscle invasive bladder cancer: an abridged Cochrane Review
10.4111/icu.20210265 · ExternalCitation · doi-reference
